New data now show that perioperative systemic therapy with apalutamide can improve outcomes after radical prostatectomy.

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Surgeons’ hands-on successes and innovators like Laënnec and John Hunter shifted authority from texts to corpses, instruments ...

During the session, Ray told the story of why this patient initially refused treatment and how he convinced her that she was worthy of survival. “When we think about ASCO, we think about science, ...

Data from the long-running HOME study links higher exposure to certain polyfluoroalkyl substances ‘forever chemicals’ with ...

Backed by 26 ministries and GRADE evidence, PAHO's new clinical pathway could accelerate access to SGLT2 inhibitors and ...

A survey found that clinicians are not discussing genetic testing with 80% of patients with kidney disease who meet ...

The largest randomized trial of its kind to date found noninferior survival and better arm morbidity among patients with breast cancer who did not undergo completion axillary lymph node dissection.

Join Drs Steven Feldman and Jonathan Kay as they examine the data on safety, switching, and confidence in psoriasis ...

From narrow volume windows to SGLT2 inhibitors and emerging devices, Drs Kevin Alexander and Sarah Cuddy discuss heart ...

A higher intake of several food colouring additives is associated with an increased risk of developing type 2 diabetes, an ...